CA3033897A1 - Pulverisation de naloxone liquide - Google Patents

Pulverisation de naloxone liquide Download PDF

Info

Publication number
CA3033897A1
CA3033897A1 CA3033897A CA3033897A CA3033897A1 CA 3033897 A1 CA3033897 A1 CA 3033897A1 CA 3033897 A CA3033897 A CA 3033897A CA 3033897 A CA3033897 A CA 3033897A CA 3033897 A1 CA3033897 A1 CA 3033897A1
Authority
CA
Canada
Prior art keywords
formulation
formulations
impurity
naloxone
liquid spray
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA3033897A
Other languages
English (en)
Other versions
CA3033897C (fr
Inventor
Kiran AMANCHA
Shivani CHILAMPALLI
Thrimoorthy Potta
Ningxin YAN
Venkat R. Goskonda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hikma Pharmaceuticals USA Inc
Original Assignee
Insys Development Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/238,909 external-priority patent/US10722510B2/en
Priority claimed from US15/601,331 external-priority patent/US10617686B2/en
Application filed by Insys Development Co Inc filed Critical Insys Development Co Inc
Publication of CA3033897A1 publication Critical patent/CA3033897A1/fr
Application granted granted Critical
Publication of CA3033897C publication Critical patent/CA3033897C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des formulations liquides stables contenant de la naloxone, un de ses sels pharmaceutiquement acceptables ou un de ses dérivés. L'invention concerne en outre des procédés permettant de traiter la dépendance aux opioïdes, la surdose d'opioïdes et l'insensibilité congénitale à la douleur avec anhidrose par l'administration des formulations liquides de la présente invention par voie intranasale à un patient en ayant besoin. En outre, l'invention concerne un procédé de traitement de la dépendance aux opioïdes, d'une surdose d'opioïdes et d'une insensibilité congénitale à la douleur avec anhidrose par l'administration intranasale des formulations de naloxone de la présente invention.
CA3033897A 2016-08-17 2017-08-10 Pulverisation de naloxone liquide Active CA3033897C (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US15/238,909 US10722510B2 (en) 2014-07-08 2016-08-17 Liquid naloxone spray
US15/238,909 2016-08-17
US15/601,331 2017-05-22
US15/601,331 US10617686B2 (en) 2014-07-08 2017-05-22 Liquid naloxone spray
PCT/US2017/046198 WO2018034920A1 (fr) 2016-08-17 2017-08-10 Pulvérisation de naloxone liquide

Publications (2)

Publication Number Publication Date
CA3033897A1 true CA3033897A1 (fr) 2018-02-22
CA3033897C CA3033897C (fr) 2024-03-26

Family

ID=61197156

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3033897A Active CA3033897C (fr) 2016-08-17 2017-08-10 Pulverisation de naloxone liquide

Country Status (7)

Country Link
EP (1) EP3500261A4 (fr)
JP (2) JP7114570B2 (fr)
CN (1) CN109922805A (fr)
AU (1) AU2017312811B2 (fr)
CA (1) CA3033897C (fr)
MA (1) MA45995A (fr)
WO (1) WO2018034920A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113453665A (zh) * 2019-02-21 2021-09-28 药品生产公司 用于舌下和/或经颊施用的纳洛酮制剂

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8580801B2 (en) 2008-07-23 2013-11-12 Robert I. Henkin Phosphodiesterase inhibitor treatment
US10598672B2 (en) 2014-02-18 2020-03-24 Cyrano Therapeutics, Inc. Methods and compositions for diagnosing and treating loss and/or distortion of taste or smell
JP7114570B2 (ja) * 2016-08-17 2022-08-08 ヒクマ・ファーマシューティカルズ・ユー・エス・エイ・インコーポレイテッド 液体ナロキソンスプレー
US20180193332A1 (en) * 2017-10-09 2018-07-12 Adapt Pharma Operations Limited Low-temperature stable opioid antagonist solutions
CN113573705A (zh) * 2018-12-19 2021-10-29 诺迪克控股公司 鼻内利多卡因的治疗组合物
CN116474219A (zh) * 2019-06-28 2023-07-25 四川普锐特药业有限公司 保持给药均一度的药物流体分配器及右美托咪定鼻喷器
CA3166250A1 (fr) 2020-02-05 2021-08-12 Gregory G. Plucinski Produits medicamenteux destines a etre administres par voie intranasale et utilisations associees
JP7606530B2 (ja) 2020-03-24 2024-12-25 シラノ セラピューティクス， インコーポレイテッド コロナウイルス感染症による化学感覚機能障害の治療
KR20240134157A (ko) * 2022-01-06 2024-09-06 시라노 테라퓨틱스, 아이엔씨. 파킨슨 치료제의 개선된 코 투여

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US14730A (en) 1856-04-22 Improvement in corn-harvesters
US585A (en) 1838-01-27 Apparatus for extinguishing sparks in the chimneys oe steam-boilers
CN1575795A (zh) 2003-06-25 2005-02-09 中国人民解放军军事医学科学院毒物药物研究所 盐酸纳洛酮鼻腔喷雾剂
US8627816B2 (en) * 2011-02-28 2014-01-14 Intelliject, Inc. Medicament delivery device for administration of opioid antagonists including formulations for naloxone
MY194947A (en) 2011-05-13 2022-12-27 Euro Celtique Sa Intranasal pharmaceutical dosage forms comprising naloxone
SMT202100546T1 (it) * 2011-09-19 2021-11-12 Orexo Ab Compresse per via sublinguale resistenti all'abuso comprendenti buprenorfina e naloxone
WO2014018098A1 (fr) 2012-07-26 2014-01-30 DePuy Synthes Products, LLC Implant expansible
CA2881144A1 (fr) * 2012-11-09 2014-05-09 Purdue Pharma Compositions pharmaceutiques comprenant de l'hydromorphone et de la naloxone
DK3043777T3 (da) 2013-09-10 2020-07-20 Fresh Cut Dev Llc Sublingual buprenorphinspray
CN103637987B (zh) 2013-12-09 2015-12-02 韩彬 羟考酮的液体药物组合物
US9192570B2 (en) 2013-12-20 2015-11-24 AntiOP, Inc. Intranasal naloxone compositions and methods of making and using same
HK1231370A1 (zh) 2014-03-14 2017-12-22 欧皮安特制药有限公司 鼻用药物产品及其使用方法
US9480644B2 (en) 2014-03-14 2016-11-01 Opiant Pharmaceuticals, Inc. Nasal drug products and methods of their use
US20160199294A1 (en) * 2014-07-08 2016-07-14 Insys Development Company, Inc. Sublingual naloxone spray
CA2954370A1 (fr) * 2014-07-08 2016-01-14 Insys Pharma, Inc. Aerosol sublingual de naloxone
JP7114570B2 (ja) 2016-08-17 2022-08-08 ヒクマ・ファーマシューティカルズ・ユー・エス・エイ・インコーポレイテッド 液体ナロキソンスプレー

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113453665A (zh) * 2019-02-21 2021-09-28 药品生产公司 用于舌下和/或经颊施用的纳洛酮制剂
US12303597B2 (en) 2019-02-21 2025-05-20 Pharmaceutical Productions, Inc. Naloxone formulations for sublingual and/or buccal administration

Also Published As

Publication number Publication date
MA45995A (fr) 2019-06-26
EP3500261A4 (fr) 2020-05-06
JP2019528278A (ja) 2019-10-10
AU2017312811A1 (en) 2019-03-07
CA3033897C (fr) 2024-03-26
CN109922805A (zh) 2019-06-21
AU2017312811A8 (en) 2019-03-14
EP3500261A1 (fr) 2019-06-26
WO2018034920A1 (fr) 2018-02-22
JP7455157B2 (ja) 2024-03-25
AU2017312811B2 (en) 2023-03-16
JP7114570B2 (ja) 2022-08-08
JP2022119843A (ja) 2022-08-17

Similar Documents

Publication Publication Date Title
CA3033897C (fr) Pulverisation de naloxone liquide
US12414915B2 (en) Liquid naloxone spray
US10617686B2 (en) Liquid naloxone spray
US10441538B2 (en) Liquid naloxone spray
US10722510B2 (en) Liquid naloxone spray
EP3043777B1 (fr) Spray sublingual contenant de la buprénorphine
US9642848B2 (en) Sublingual naloxone spray
EP3612173B1 (fr) Formulations pour la pulvérisation d'épinéphrine
US20160199294A1 (en) Sublingual naloxone spray
US10973814B2 (en) Liquid naloxone spray
US9839611B2 (en) Sublingual buprenorphine spray
WO2019143925A1 (fr) Compositions liquides de rizatriptan
CA3060078C (fr) Formulations pour la pulverisation d'epinephrine
US20160361307A1 (en) Sublingual buprenorphine spray
HK1225653B (en) Sublingual buprenorphine spray

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220510

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240809

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240809

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240809

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250724

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250826